Home Daily Stock Opinions and Ratings Teva Pharmaceutical (TEVA-N)

Trending stocks today

Enbridge IBM Common Stock Saputo Inc. Smith & Nephew PLC Electronic Arts Inc BigBear.ai Holdings Boyd Gaming Corp. Tesla Inc Apple Inc Deckers Outdoor Corp. Financial Select Sector SPDR Fund Royalty Pharma plc Sanofi-Aventis Astrazeneca P L C Cameco Corporation Altagas Ltd Generac UiPath Inc. Adobe Systems Pembina Pipeline Corp

Teva Pharmaceutical (TEVA-N)

NEW AI Investor Insights
66 watching

NYSE:TEVA

16.60
0.21 (1.25%) 1d
Feb 11, 2025, 8:04 pm
0

Related posts

Alibaba IPO the biggest of 2019 as U.S. Attorney subpoenas big pharma
DON'T BUY

Teva Pharmaceutical(TEVA-N)

05/01/2024
Teva Pharmaceutical

It's cheap and has momentum, but that's all it has now. It never grabbed him.

biotechnology / pharmaceutical
Jim Cramer - Mad Money
$11.330
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

04/08/2023
Teva Pharmaceutical

Massive share price appreciation not sustainable. 
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time. 

biotechnology / pharmaceutical
Lorne Steinberg
$9.745
Unknown
UnlockRating
BUY ON WEAKNESS

Teva Pharmaceutical(TEVA-N)

06/01/2023
Teva Pharmaceutical
Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.
biotechnology / pharmaceutical
David Fingold
$10.520
Unknown
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

17/03/2022
Teva Pharmaceutical
He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.
biotechnology / pharmaceutical
Brian Acker, CA
$7.805
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

11/11/2021
Teva Pharmaceutical
Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.
biotechnology / pharmaceutical
Lorne Steinberg
$9.545
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

15/04/2021
Teva Pharmaceutical
Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.
biotechnology / pharmaceutical
Christine Poole
$10.845
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

19/10/2020
Teva Pharmaceutical

Doesn't offer growth. The stock is weak and will stay weak.

biotechnology / pharmaceutical
Jim Cramer - Mad Money
$9.290
Unknown
UnlockRating
BUY

Teva Pharmaceutical(TEVA-N)

27/02/2020
Teva Pharmaceutical
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
biotechnology / pharmaceutical
Brian Acker, CA
$12.210
Unknown
UnlockRating
HOLD

Teva Pharmaceutical(TEVA-N)

28/11/2019
Teva Pharmaceutical
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology / pharmaceutical
Bruce Murray
$10.450
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

15/08/2019
Teva Pharmaceutical
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology / pharmaceutical
Lorne Steinberg
$6.160
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

17/07/2019
Teva Pharmaceutical
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
biotechnology / pharmaceutical
Paul MacDonald
$8.110
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

03/07/2019
Teva Pharmaceutical
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
biotechnology / pharmaceutical
Norman Levine
$9.600
No
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

02/07/2019
Teva Pharmaceutical
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
biotechnology / pharmaceutical
Paul Harris, CFA
$9.430
Unknown
UnlockRating
DON'T BUY

Teva Pharmaceutical(TEVA-N)

22/05/2019
Teva Pharmaceutical
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
biotechnology / pharmaceutical
Norman Levine
$11.540
No
UnlockRating
COMMENT

Teva Pharmaceutical(TEVA-N)

03/05/2019
Teva Pharmaceutical
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
biotechnology / pharmaceutical
Paul MacDonald
$15.180
No
UnlockRating
Showing 1 to 15 of 272 entries
Next PageNext Page

Teva Pharmaceutical(TEVA-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Teva Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Teva Pharmaceutical(TEVA-N) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N

Is Teva Pharmaceutical a buy or a sell?

In the last year, there was no coverage of Teva Pharmaceutical published on Stockchase.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

0 stock analysts on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2025-02-11, Teva Pharmaceutical (TEVA-N) stock closed at a price of $16.6.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

GS-NGoldman Sachs
Goldman Sachs
$648.05
-2.48 (-0.38%)
VIU-TVanguard FTSE Developed All Cap ex North Amer Idx ETF.
Vanguard FTSE Developed All Cap ex North Amer Idx ETF.
$36.30
0.12 (0.33%)
PI-QImpinj Inc
Impinj Inc
$104.19
-0.65 (-0.63%)
ILMN-QIllumina Inc.
Illumina Inc.
$101.64
-3.35 (-3.41%)
DIS-NWalt Disney Co.
Walt Disney Co.
$108.82
-0.46 (-0.42%)
Advertising

Today's Top Picks

PPL-TPembina Pipeline Corp
Pembina Pipeline Corp
$52.62
0.14 (0.27%)
ADBE-QAdobe Systems
Adobe Systems
$458.94
7.84 (1.68%)
PATH-NUiPath Inc.
UiPath Inc.
$14.05
-0.18 (-1.30%)
GNRC-NGenerac
Generac
$141.70
-3.37 (-2.44%)
ALA-TAltagas Ltd
Altagas Ltd
$34.87
0.11 (0.31%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

NTRA-QNatera
Natera
$168.20
-3.99 (-2.43%)
VRTX-QVertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
$458.20
-11.77 (-2.64%)
IONQ-NIonQ, Inc.
IonQ, Inc.
$38.98
-2.09 (-5.67%)
MCD-NMcDonalds
McDonalds
$309.88
1.46 (0.47%)
QQQ-QInvesco QQQ Trust Series 1
Invesco QQQ Trust Series 1
$528.77
-0.48 (-0.09%)

Most Recent Experts

Berman

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Linde

Teal Linde

Linde Equity Report

Stockchase

Stockchase Insights

5i Research

Terranova

Joe Terranova

Virtus Investment Partners

Lebenthal

Jim Lebenthal

Cerity Partners

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.